卵巢癌女性的手术再入院与生存:短期质量指标是否在激励长期生存下降?
基于美国国家癌症数据库2006至2012年20,853例IIIC期上皮性卵巢癌患者,比较新辅助化疗(NACT)与初次肿瘤细胞减灭术(PDS)后的30天再入院和总生存。NACT与任何再入院风险降低48%相关(aRR 0.52,95%CI 0.45-0.60),但同时也与死亡风险增加33%相关(HR 1.33,95%CI 1.29-1.40)。
要点
- IIIC期上皮性卵巢癌中,15.6%接受NACT,11.6%在术后30天内再入院,其中59%为非计划再入院。
- 校正年龄、种族、保险、组织学、诊断年份和Charlson合并症指数后,NACT较PDS与任何再入院风险降低48%相关(aRR 0.52,95%CI 0.45-0.60)。
- 同一人群中,NACT较PDS与死亡风险增加33%相关(HR 1.33,95%CI 1.29-1.40)。
核心结论
- 在IIIC期上皮性卵巢癌女性中,与PDS相比,NACT与再入院率降低和生存期缩短均相关。
- 选择偏倚可能解释部分观察到的生存差异,但当前对术后再入院等短期医院-wide质量指标的关注,可能在卵巢癌人群中产生与长期目标不一致的激励。
研究设计与样本
- 基于美国国家癌症数据库(NCDB)2006至2012年数据的回顾性队列研究,纳入接受化疗和手术的IIIC期上皮性卵巢癌初发病例20,853例。
- 30天再入院分为计划再入院和非计划再入院,采用对数二项模型估计风险比及95%置信区间,采用Cox比例风险模型进行生存分析。
主要发现
- 20,853例IIIC期上皮性卵巢癌女性中,15.6%(n=3242)接受NACT,11.6%(n=2427)在术后30天内再入院,其中59%(n=1421)为非计划再入院。
- 校正年龄、种族、保险、组织学、诊断年份和Charlson合并症指数评分后,与PDS相比,NACT与任何再入院风险降低48%相关(aRR 0.52,95%CI 0.45-0.60)。
- 同一人群中,校正相同因素后,接受NACT与死亡风险增加33%相关(HR 1.33,95%CI 1.29-1.40)。
临床怎么用
- 原文未据此给出临床推荐,作者指出当前对术后再入院等短期医院-wide质量指标的关注,可能在卵巢癌人群中产生与长期目标不一致的激励。
局限性
- 选择偏倚可能解释部分观察到的生存差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the association between treatment with neoadjuvant chemotherapy (NACT) or primary debulking surgery (PDS) and readmission after surgical hospitalization as well as overall survival among women with stage IIIC epithelial ovarian cancer (EOC). METHODS: We identified incident cases of stage IIIC EOC treated with both chemotherapy and surgery in the National Cancer Database (NCDB) from 2006 to 2012. 30-day readmissions were categorized as planned or unplanned. Log binomial models were used to estimate risk ratios and 95% confidence intervals. Survival analysis was performed using cox proportional hazards models. RESULTS: We identified 20,853 women with stage IIIC EOC. 15.6% (n=3242) were treated with NACT and 11.6% (n=2427) were readmitted within 30days of surgery, 59% (n=1421) were unplanned. NACT was associated with a 48% reduction in the risk of any readmission (aRR 0.52 95%CI 0.45-0.60) compared to PDS with adjustment for age, race, insurance, histology, year of diagnosis, and Charlson co-morbidity index score. However, in the same population, receipt of neoadjuvant chemotherapy was also associated with a 33% increase in the rate of death (HR 1.33 95%CI 1.29-1.40) with adjustment for the same factors. CONCLUSIONS: Among women with stage IIIC EOC, NACT is associated with both decreased rates of readmission and decreased survival compared to PDS. While selection bias may account for some of the observed differences in survival, the current focus on short-term hospital-wide quality metrics, such as postoperative readmission, in the ovarian cancer population, may be creating incentives inconsistent with long-term goals.
引用
- Barber EL, Rossi EC, Gehrig PA, et al. Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival? Gynecol Oncol. 2017. PMID: 28941658. doi:10.1016/j.ygyno.2017.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。